Inventages Venture Capital

Gunnar Weikert, Chairman and Managing Partner, has led the firm since its 1996 founding. He oversees all investment activity and strategic direction. The firm does not publicly list a separate CIO, investment committee, or additional managing partners, suggesting a concentrated decision-making structure.

Inventages operates as a venture-capital subsidiary within the Nestlé Health Science ecosystem. This affiliation gives portfolio companies potential access to Nestlé's global distribution network, clinical-research capabilities, and consumer-packaged-goods expertise. However, it also means Inventages functions less as an independent financial sponsor and more as a strategic corporate venture arm, which can shape target selection and holding periods.

The firm deploys across early-stage (seed and startup) through expansion and late-stage venture rounds, per its stated strategy. It also engages in buyout transactions where a nutrition or digital-health asset fits the strategic scope. The absence of publicly disclosed fund sizes suggests deal-level capital allocation rather than fixed-stage mandates.

Inventages primarily executes direct equity and minority co-investments in operating companies. There is no public record of the firm acting as a limited partner in third-party venture funds. Its model emphasizes board-level engagement and corporate-synergy capture rather than passive fund-of-funds exposure.

Core sectors include digital health, personalized nutrition, microbiome therapeutics, metabolic-health platforms, and food-as-medicine interventions. The firm does not publicly list exclusions, but its deal history shows a focus on regulated, clinically validated products rather than general wellness or fitness-tech plays.

Public record indicates a primary focus on North America and Western Europe, with selective activity in Israel and Asia-Pacific innovation clusters. Its Bahamas headquarters serves as a corporate base, while operational footprint relies on Nestlé's global R&D and commercial centers for diligence and portfolio support.

Inventages will co-invest alongside other venture and growth-equity firms, particularly in later-stage rounds where strategic value can complement purely financial syndicate support. The firm does not operate a formal co-investor club or publicly disclose a standard co-investment notice period, so terms are likely negotiated deal-by-deal within the Nestlé Health Science governance framework.